Table 2 LAR, use of Salbutamol, FEV ₁ and eNO during provocation period

LAR (all subjects, n = 27)

[n]

8

9

7

11

Use of salbutamol (n = 27)

[puffs, mean ± SD]

0.85 ± 1.6

0.74 ± 1.5

0.74 ± 1.2

1.18 ± 2.0

0.59

Pre-challenge FEV₁ (n = 18)

[absolute L, mean ± SD]

4.03 ± 0.93

3.86 ± 0.88

3.79 ± 0.99

3.83 ± 0.92

3.83 ± 0.90

<0.001

Pre-challenge FEV₁ (n = 18)

[% pred, mean ± SD]

101.9 ± 15.6

97.4 ± 13.3

95.5 ± 17.6

97.1 ± 16.1

96.7 ± 14.7

<0.001

eNO (n = 18)

[ppb, mean ± SD]

29.4 ± 17.2

65.4 ± 31.2

93.5 ± 45.3

110.5 ± 51.4

114.5 ± 53.9

<0.0001